Drug-based cancer therapy to overcome immune resistance by steering tumor evolution

Autores
Fernandez, Ariel
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
We argue that therapy must lead rather than follow vis-à-vis cancer evolution. Clinical experience suggests that the evading phenotype resulting from treatment can never be fully anticipated or eliminated when a single source of selection pressure is applied during treatment. Thus, therapy must steer cancer evolution and LIC may well become the underlying paradigm to overcome resistance in a therapeutic context where immune surveillance is maintained.
Fil: Fernandez, Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; Argentina
Materia
CANCER EVOLUTION
CANCER RESISTANCE
IMMUNE CHECKPOINT INHIBITOR
IMMUNE EVASION
PHOSPHOINOSITIDE-3 KINASE INHIBITOR
TARGETED THERAPY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/151968
Acceder
id CONICETDig_c5836be73b8fe15c21708ab098efa3e3
oai_identifier_str oai:ri.conicet.gov.ar:11336/151968
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Drug-based cancer therapy to overcome immune resistance by steering tumor evolutionFernandez, ArielCANCER EVOLUTIONCANCER RESISTANCEIMMUNE CHECKPOINT INHIBITORIMMUNE EVASIONPHOSPHOINOSITIDE-3 KINASE INHIBITORTARGETED THERAPYhttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3We argue that therapy must lead rather than follow vis-à-vis cancer evolution. Clinical experience suggests that the evading phenotype resulting from treatment can never be fully anticipated or eliminated when a single source of selection pressure is applied during treatment. Thus, therapy must steer cancer evolution and LIC may well become the underlying paradigm to overcome resistance in a therapeutic context where immune surveillance is maintained.Fil: Fernandez, Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; ArgentinaInforma Healthcare2019-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/151968Fernandez, Ariel; Drug-based cancer therapy to overcome immune resistance by steering tumor evolution; Informa Healthcare; Expert Opinion On Drug Discovery; 14; 1; 1-2019; 5-81746-0441CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/17460441.2019.1550066info:eu-repo/semantics/altIdentifier/doi/10.1080/17460441.2019.1550066info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:59:18Zoai:ri.conicet.gov.ar:11336/151968instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:59:19.127CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Drug-based cancer therapy to overcome immune resistance by steering tumor evolution
title Drug-based cancer therapy to overcome immune resistance by steering tumor evolution
spellingShingle Drug-based cancer therapy to overcome immune resistance by steering tumor evolution
Fernandez, Ariel
CANCER EVOLUTION
CANCER RESISTANCE
IMMUNE CHECKPOINT INHIBITOR
IMMUNE EVASION
PHOSPHOINOSITIDE-3 KINASE INHIBITOR
TARGETED THERAPY
title_short Drug-based cancer therapy to overcome immune resistance by steering tumor evolution
title_full Drug-based cancer therapy to overcome immune resistance by steering tumor evolution
title_fullStr Drug-based cancer therapy to overcome immune resistance by steering tumor evolution
title_full_unstemmed Drug-based cancer therapy to overcome immune resistance by steering tumor evolution
title_sort Drug-based cancer therapy to overcome immune resistance by steering tumor evolution
dc.creator.none.fl_str_mv Fernandez, Ariel
author Fernandez, Ariel
author_facet Fernandez, Ariel
author_role author
dc.subject.none.fl_str_mv CANCER EVOLUTION
CANCER RESISTANCE
IMMUNE CHECKPOINT INHIBITOR
IMMUNE EVASION
PHOSPHOINOSITIDE-3 KINASE INHIBITOR
TARGETED THERAPY
topic CANCER EVOLUTION
CANCER RESISTANCE
IMMUNE CHECKPOINT INHIBITOR
IMMUNE EVASION
PHOSPHOINOSITIDE-3 KINASE INHIBITOR
TARGETED THERAPY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv We argue that therapy must lead rather than follow vis-à-vis cancer evolution. Clinical experience suggests that the evading phenotype resulting from treatment can never be fully anticipated or eliminated when a single source of selection pressure is applied during treatment. Thus, therapy must steer cancer evolution and LIC may well become the underlying paradigm to overcome resistance in a therapeutic context where immune surveillance is maintained.
Fil: Fernandez, Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; Argentina
description We argue that therapy must lead rather than follow vis-à-vis cancer evolution. Clinical experience suggests that the evading phenotype resulting from treatment can never be fully anticipated or eliminated when a single source of selection pressure is applied during treatment. Thus, therapy must steer cancer evolution and LIC may well become the underlying paradigm to overcome resistance in a therapeutic context where immune surveillance is maintained.
publishDate 2019
dc.date.none.fl_str_mv 2019-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/151968
Fernandez, Ariel; Drug-based cancer therapy to overcome immune resistance by steering tumor evolution; Informa Healthcare; Expert Opinion On Drug Discovery; 14; 1; 1-2019; 5-8
1746-0441
CONICET Digital
CONICET
url http://hdl.handle.net/11336/151968
identifier_str_mv Fernandez, Ariel; Drug-based cancer therapy to overcome immune resistance by steering tumor evolution; Informa Healthcare; Expert Opinion On Drug Discovery; 14; 1; 1-2019; 5-8
1746-0441
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/17460441.2019.1550066
info:eu-repo/semantics/altIdentifier/doi/10.1080/17460441.2019.1550066
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Informa Healthcare
publisher.none.fl_str_mv Informa Healthcare
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269574606618624
score 13.13397

Publicaciones similares